Results 51 to 60 of about 7,735 (172)
The Discovery of Dabigatran Etexilate [PDF]
Frontiers in Pharmacology, 2013 Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation. Thrombin is a key serine protease in the coagulation cascade and numerous efforts have been made to develop safe and effective orally active direct thrombin inhibitors (DTIs).
van Ryn, Joanne +6 more
openaire +3 more sources
Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
Frontiers in Cardiovascular Medicine, 2022 PurposeDabigatran concentrations monitoring are gaining importance of special situations, but limited data are available for the expected peak and trough levels. The hemoclot thrombin inhibitor (HTI) is dabigatran-calibrated quantitative determination of
Zhiyan Liu +9 more
doaj +1 more source
Pulmonary Embolism—A Century of Progress
ANZ Journal of Surgery, EarlyView.Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley +1 more source
Dabigatran and apolipoprotein B [PDF]
Heart, 2015 Dabigatran is the first of a series of new direct acting oral anticoagulants that was clinically introduced for the prevention of ischaemic stroke in patients with atrial fibrillation (AF). In the randomized evaluation of long-term anticoagulation therapy (RE-LY) study, dabigatran was shown to be superior or non-inferior to warfarin in preventing ...
openaire +2 more sources
Discovery of a Reversible Sub‐Picomolar Thrombin Inhibitor Using DCC
Angewandte Chemie, Volume 138, Issue 38, 14 September 2026.An ultrapotent yet fully reversible trivalent thrombin inhibitor discovered through screening a large dynamic combinatorial library (DCL) of 125 000 members of self‐assembled fragments. The innovative approach leverages size‐exclusion‐based affinity selection, coupled with MALDI‐TOF mass spectrometry readout, enabling the full workflow to be completed ...
Millicent Dockerill +2 more
wiley +2 more sources
Alimentary Pharmacology &Therapeutics, EarlyView.Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala +13 more
wiley +1 more source
Dabigatran pharmacokinetics (PK).
, 2019 PK of dabigatran etexilate administrated by one dose of 10 mg/kg intraperitoneal. Plasma dabigatran (p-dabigatran) were measured in two healthy rats at each time point (n = 14).
Jens Peter Goetze (316975) +9 more
core +1 more source
DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS
Атеротромбоз, 2015 This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
PERANAN IDARUCIZUMAB UNTUK MENETRALISIR EFEK ANTIKOAGULAN DABIGATRAN [PDF]
, 2019 Latar Belakang: Dabigatran etexilate (Pradaxa) telah disetujui oleh FDA dan Uni Eropa sebagai antikoagulan untuk mencegah stroke dan emboli sistemik pada pasien dengan atrial fibrilasi non-valvular dan satu atau lebih faktor risiko lain.
Soejitno, Andreas +1 more
core +1 more source